Radiation sensitization with redox modulators: a promising approach - PubMed (original) (raw)
Review
Radiation sensitization with redox modulators: a promising approach
Abby Rosenberg et al. Int J Radiat Oncol Biol Phys. 2006.
Abstract
Purpose: Radiation therapy plays a critical role in the local and regional control of malignant tumors. Its efficacy, however, is limited by a number of factors, including toxicity, tumor hypoxia, and tumor genetics. Recent attempts to enhance the efficacy of radiation therapy have focused on biologic agents that modulate reduction/oxidation reactions within tumor cells.
Methods and materials: We review five promising redox modulators that are in development. Tirapazamine and AQ4N are known as "hypoxic cell sensitizers" and are toxic in areas of low oxygen tension. RSR13 facilitates delivery of oxygen to tumor cells, thereby rendering them more sensitive to radiation. Motexafin gadolinium, with a porphyrin-like structure, selectively accumulates in tumor cells and thereby enhances radiation-induced DNA damage. HIF-1 inhibitors target a transcription factor that regulates hypoxia-related events and cell survival.
Results: Our review of each agent included a thorough search of published preclinical and clinical data, including that presented in abstracts and posters at international meetings. Our objectives were not to identify a superior mechanism or drug, but rather to summarize the available safety and efficacy data.
Conclusion: Clearly, there is an unmet need for safer agents that augment the efficacy of radiation therapy. This review highlights five promising redox modulators that are in development. None has yet been approved by the Food and Drug Administration. These drugs were selected for discussion because they exemplify the current investigative landscape of radiosensitizers and are indicative of future directions in this area. These radiation sensitizers have the potential to succeed where others have failed, by locally increasing the radiosensitivity of tumor cells without enhancing that of surrounding normal tissues.
Similar articles
- Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
De Ridder M, Van Esch G, Engels B, Verovski V, Storme G. De Ridder M, et al. Bull Cancer. 2008 Mar;95(3):282-91. doi: 10.1684/bdc.2008.0592. Bull Cancer. 2008. PMID: 18390408 Review. - Novel radiation sensitizers targeting tissue hypoxia.
Rowinsky EK. Rowinsky EK. Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):61-70. Oncology (Williston Park). 1999. PMID: 10550828 Review. - [Radiation sensitizers: with special reference to hypoxic cell sensitizers].
Onoyama Y, Nakajima T, Tanaka M. Onoyama Y, et al. Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 1):894-903. Gan To Kagaku Ryoho. 1986. PMID: 3963856 Japanese. - Efaproxiral: a radiation enhancer used in brain metastases from breast cancer.
Charpentier MM. Charpentier MM. Ann Pharmacother. 2005 Dec;39(12):2038-45. doi: 10.1345/aph.1G077. Epub 2005 Oct 25. Ann Pharmacother. 2005. PMID: 16249270 Review. - Chemical radiosensitizers for use in radiotherapy.
Wardman P. Wardman P. Clin Oncol (R Coll Radiol). 2007 Aug;19(6):397-417. doi: 10.1016/j.clon.2007.03.010. Epub 2007 May 2. Clin Oncol (R Coll Radiol). 2007. PMID: 17478086 Review.
Cited by
- Radiosensitization effect of quinoline-indole-schiff base derivative 10E on non-small cell lung cancer cells in vitro and in tumor xenografts.
Liu H, Wang Q, Lan W, Liu D, Huang J, Yao J. Liu H, et al. Invest New Drugs. 2024 Aug;42(4):405-417. doi: 10.1007/s10637-024-01451-1. Epub 2024 Jun 17. Invest New Drugs. 2024. PMID: 38880855 - Anti-radiation effect of MRN-100: a hydro-ferrate fluid, in vivo.
Ghoneum M, Badr El-Din NK, Alaa El-Dein M. Ghoneum M, et al. J Radiat Res. 2024 Mar 22;65(2):145-158. doi: 10.1093/jrr/rrad095. J Radiat Res. 2024. PMID: 38247158 Free PMC article. - X-ray crystallography and sickle cell disease drug discovery-a tribute to Donald Abraham.
Donkor AK, Pagare PP, Mughram MHA, Safo MK. Donkor AK, et al. Front Mol Biosci. 2023 May 24;10:1136970. doi: 10.3389/fmolb.2023.1136970. eCollection 2023. Front Mol Biosci. 2023. PMID: 37293554 Free PMC article. Review. - Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
Smith PJ, McKeown SR, Patterson LH. Smith PJ, et al. IUBMB Life. 2023 Jan;75(1):40-54. doi: 10.1002/iub.2619. Epub 2022 May 2. IUBMB Life. 2023. PMID: 35499745 Free PMC article. Review. - Application of Radiosensitizers in Cancer Radiotherapy.
Gong L, Zhang Y, Liu C, Zhang M, Han S. Gong L, et al. Int J Nanomedicine. 2021 Feb 12;16:1083-1102. doi: 10.2147/IJN.S290438. eCollection 2021. Int J Nanomedicine. 2021. PMID: 33603370 Free PMC article. Review.